Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 14/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20443196 | 0.82 | EPAS1 (0.45) | EPAS1ALDH1A1CA2 | |
| SCHEMBL5150927 | 0.79 | VCAM1 (0.52) | EPAS1ALDH1A1CA2POLB | |
| SCHEMBL29555632 | 0.79 | VCAM1 (0.52) | EPAS1ALDH1A1CA2POLB | |
| SCHEMBL24456745 | 0.79 | EPAS1 (0.59) | EPAS1ALDH1A1ESPL1CA2LMNA | |
| SCHEMBL20526549 | 0.79 | ALDH1A1 (0.70) | EPAS1ALDH1A1ESPL1CA2LMNA | |
| SCHEMBL15068035 | 0.78 | CA2 (0.61) | CA2 | |
| SCHEMBL16555813 | 0.77 | EPAS1 (0.56) | EPAS1ALDH1A1MEN1KMT2A | |
| SCHEMBL20442955 | 0.77 | PNMT (0.42) | EPAS1CA2 | |
| SCHEMBL16555605 | 0.76 | EPAS1 (1.00) | EPAS1 | |
| SCHEMBL23358269 | 0.76 | CNR2 (0.42) | EPAS1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-110372550-B | Aryl ethers and their use | 佩洛通治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3417851-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3417852-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3043784-B9 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3043784-A1 | ARYL ETHERS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2015035223-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885ALDH1A1 497/4885ESPL1 4810/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | EPAS1 2025/4885ALDH1A1 1794/4885ESPL1 1929/4885 |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885ALDH1A1 497/4885ESPL1 4810/4885 |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885ALDH1A1 497/4885ESPL1 4810/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | EPAS1 2025/4885ALDH1A1 1794/4885ESPL1 1929/4885 |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885ALDH1A1 497/4885ESPL1 4810/4885 |
| US-10597366-B2 | Aryl ethers and uses thereof | HIF1AN, EGLN2, VHL | EPAS1 9/4885ALDH1A1 497/4885ESPL1 4810/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | EPAS1 2025/4885ALDH1A1 1794/4885ESPL1 1929/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | EPAS1 2025/4885ALDH1A1 1794/4885ESPL1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.